Top

Published in:

01-06-1998

Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy

Authors: Larry Witte, Daniel J. Hicklin, Zhenping Zhu, Bronislaw Pytowski, Helen Kotanides, Patricia Rockwell, Peter Böhlen

Published in: Cancer and Metastasis Reviews | Issue 2/1998

Title: Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy
Authors: Larry Witte
Daniel J. Hicklin
Zhenping Zhu
Bronislaw Pytowski
Helen Kotanides
Patricia Rockwell
Peter Böhlen
Publication date: 01-06-1998
Publisher: Kluwer Academic Publishers
Published in: Cancer and Metastasis Reviews / Issue 2/1998
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1023/A:1006094117427

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 2/1998

New targets, drugs, and approaches for the treatment of cancer: An overview

The erbB2 gene as a cancer therapeutic target and the tumor- and metastasis-suppressing function of E1A

Anti-adhesion cancer therapy

The pivotal role of VEGF in tumor angiogenesis: Molecular facts and therapeutic opportunities

Future developments in the selectivity of anticancer agents: Drug delivery and molecular target strategies

The molecular basis of the hypoxia response pathway: Tumour hypoxia as a therapy target

Keynote webinar | Spotlight on antibody–drug conjugates in cancer